Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 7, 2013, Pages 928-931

  Izquierdo, Luis ^a   Marques, Alexandre Ferreira ^b   Gállego, Montserrat ^c   Sanz, Sílvia ^a   Tebar, Sílvia ^c   Riera, Cristina ^c   Quintó, Llorenç ^a   Aldasoro, Edelweiss ^a   Almeida, Igor C ^b   Gascon, Joaquim ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chagas disease; Lytic anti gal antibodies; Trypanosoma cruzi

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

BLOOD; CASE CONTROL STUDY; CHAGAS DISEASE; DIAGNOSTIC USE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; LUMINESCENCE; PROCEDURES; TRYPANOSOMA CRUZI;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CASE-CONTROL STUDIES; CHAGAS DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; LUMINESCENCE; TRYPANOSOMA CRUZI;

EID: 84886904140     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276130112     Document Type: Article

References (22)

1. Almeida IC, Covas DT, Soussumi LM, Travassos LR 1997. A highly sensitive and specific chemiluminescent enzyme-linked immunosorbent assay for diagnosis of active Trypanosoma cruzi infection. Transfusion 37: 850-857.
2. Almeida IC, Ferguson MA, Schenkman S, Travassos LR 1994. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J 304: 793-802.
3. Almeida IC, Krautz GM, Krettli AU, Travassos LR 1993. Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal 7: 307-316.
4. Almeida IC, Milani SR, Gorin PA, Travassos LR 1991. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol 146: 2394-2400.
5. Andrade ALSS, Martelli CM, Oliveira RM, Silva SA, Aires AI, Soussumi LM, Covas DT, Silva LS, Andrade JG, Travassos LR, Almeida IC 2004. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 71: 594-597.
6. Andrade ALSS, Zicker F, de Oliveira RM, Silva SA, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
7. de Marchi CR, Di Noia JM, Frasch AC, Amato Neto V, Almeida IC, Buscaglia CA 2011. Evaluation of a recombinant Trypanosoma cruzi mucin-like antigen for serodiagnosis of Chagas disease. Clin Vaccine Immunol 18: 1850-1855.
8. Frey A, Di Canzio J, Zurakowski D 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41.
9. Galvão LM, Nunes RM, Cançado JR, Brener Z, Krettli AU 1993. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87: 220-223.
10. Gascon J, Bern C, Pinazo MJ 2010. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 115: 22-27.
11. Hernández P, Heimann M, Riera C, Solano M, Santalla J, Luquetti AO, Beck E 2010. Highly effective serodiagnosis for Chagas disease. Clin Vaccine Immunol 17: 1598-1604.
12. Krettli AU 2009. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem Inst Oswaldo Cruz 104 (Suppl. I): 142-151.
13. Krettli AU, Cancado JR, Brener Z 1982. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas disease. Trans R Soc Trop Med Hyg 76: 334-340.
14. Longhi SA, Brandariz SB, Lafon SO, Niborski LL, Luquetti AO, Schijman AG, Levin MJ, Gómez KA 2012. Evaluation of in-house ELISA using Trypanosoma cruzi lysate and recombinant antigens for diagnosis of Chagas disease and discrimination of its clinical forms. Clin Vaccine Immunol 17: 1598-1604.
15. Pereira-Chioccola VL, Acosta-Serrano A, de Almeida IC, Ferguson MA, Souto-Padron T, Rodrigues MM, Travassos LR, Schenkman S 2000. Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-alpha-galactosyl antibodies. J Cell Sci 113: 1299-1307.
16. Piron M, Vergés M, Muñoz J, Casamitjana N, Sanz S, Maymó RM, Hernández JM, Puig L, Portús M, Gascon J, Sauleda S 2008. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 48: 1862-1868.
17. Rassi A, Luquetti AO 2003. Specific treatment for Trypanosoma cruzi infection (Chagas disease). In KM Tyler, MA Miles (eds.), American trypanosomiasis, Springer, New York, p. 117-125.
18. Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE 2009. Eliminating Chagas disease: challenges and a roadmap. BMJ 338: b1283.
19. Riera C, Vergés M, López-Chejade P, Piron M, Gascon J, Fisa R, Gállego M, Portús M 2009. Desarrollo y evaluación de una técnica ELISA con antígeno crudo de Trypanosoma cruzi para el diagnóstico de la enfermedad de Chagas. Enferm Emerg 11: 22-29.
20. Travassos LR, Almeida IC 1993. Carbohydrate immunity in American trypanosomiasis. Springer Semin Immunopathol 15: 183-204.
21. Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, Zingales B, Luquetti AO, da Silveira JF 2003. An improved serodiagnostic test for Chagas disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion 43: 91-97.
22. Umezawa ES, Nascimento MS, Kesper Jr N, Coura JR, Borges-Pereira J, Junqueira AC, Camargo ME 1996. Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute and chronic Chagas disease. J Clin Microbiol 34: 2143-2147.